European Union - English - EMA (European Medicines Agency)

merck europe b.v.  - cetuximab - head and neck neoplasms; colorectal neoplasms - antineoplastic agents - erbitux is indicated for the treatment of patients with epidermal growth factor receptor (egfr)-expressing, ras wild-type metastatic colorectal cancer:in combination with irinotecan-based chemotherapy;in first-line in combination with folfox;as a single agent in patients who have failed oxaliplatin- and irinotecan-based therapy and who are intolerant to irinotecan.for details, see section 5.1.erbitux is indicated for the treatment of patients with squamous cell cancer of the head and neck:in combination with radiation therapy for locally advanced disease;in combination with platinum-based chemotherapy for recurrent and/or metastatic disease.

United States - English - NLM (National Library of Medicine)

merck sharp & dohme llc - varicella-zoster virus strain oka/merck live antigen (unii: gpv39zgd8c) (varicella-zoster virus strain oka/merck live antigen - unii:gpv39zgd8c) - varicella-zoster virus strain oka/merck live antigen 1350 [pfu] in 0.5 ml - varivax is a vaccine indicated for active immunization for the prevention of varicella in individuals 12 months of age and older. do not administer varivax to individuals with a history of anaphylactic or severe allergic reaction to any component of the vaccine (including neomycin and gelatin) or to a previous dose of a varicella-containing vaccine. do not administer varivax to individuals who are immunodeficient or immunosuppressed due to disease or medical therapy. disseminated varicella disease and extensive vaccine-associated rash have been reported in individuals who are immunosuppressed or immunodeficient who were inadvertently vaccinated with a varicella-containing vaccine. do not administer varivax to individuals with an active febrile illness with fever >101.3°f (>38.5°c). do not administer varivax to individuals with active, untreated tuberculosis (tb). do not administer varivax to individuals who are pregnant or planning on becoming pregnant in the next 3 months. wild-type varicella is known to cau

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

merck serono ltd - cetrorelix acetate - powder and solvent for solution for injection - 250microgram

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

merck sharp & dohme (uk) ltd - varicella-zoster virus live attenuated (oka/merck strain) - powder and solvent for suspension for injection

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

merck sharp & dohme ltd - varicella-zoster virus live attenuated (oka/merck strain) - powder and solvent for suspension for injection

Ireland - English - HPRA (Health Products Regulatory Authority)

merck serono (ireland) limited - bisoprolol hemifumarate - film-coated tablet - 1.25 milligram(s) - beta blocking agents, selective; bisoprolol

Ireland - English - HPRA (Health Products Regulatory Authority)

merck serono (ireland) limited - bisoprolol hemifumarate - film-coated tablet - 10 milligram(s) - beta blocking agents, selective; bisoprolol

Ireland - English - HPRA (Health Products Regulatory Authority)

merck serono (ireland) limited - bisoprolol hemifumarate - film-coated tablet - 2.5 milligram(s) - beta blocking agents, selective; bisoprolol

Ireland - English - HPRA (Health Products Regulatory Authority)

merck serono (ireland) limited - bisoprolol hemifumarate - film-coated tablet - 3.75 milligram(s) - beta blocking agents, selective; bisoprolol

Ireland - English - HPRA (Health Products Regulatory Authority)

merck serono (ireland) limited - bisoprolol hemifumarate - film-coated tablet - 5 milligram(s) - beta blocking agents, selective; bisoprolol